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Abstract
Background: A dearth of laboratory tests to study actual human approach-avoidance behavior has complicated
translational research on anxiety. The elevated plus-maze (EPM) is the gold standard to assess approach-avoidance
behavior in rodents.
Methods: Here, we translated the EPM to humans using mixed reality through a combination of virtual and real-
world elements. In two validation studies, we observed participants’ anxiety on a behavioral, physiological, and
subjective level.
Results: Participants reported higher anxiety on open arms, avoided open arms, and showed an activation of
endogenous stress systems. Participants’ with high anxiety exhibited higher avoidance. Moreover, open arm avoidance
was moderately predicted by participants’ acrophobia and sensation seeking, with opposing influences. In a
randomized, double blind, placebo controlled experiment, GABAergic stimulation decreased avoidance of open
arms while alpha-2-adrenergic antagonism increased avoidance.
Conclusion: These findings demonstrate cross-species validity of open arm avoidance as a translational measure
of anxiety. We thus introduce the first ecologically valid assay to track actual human approach-avoidance behavior
under laboratory conditions.
Keywords: Virtual reality, Approach, Avoidance, Risk assessment, Behavioral assay, Anxiety disorder, Acrophobia,
Sensation seeking, Yohimbine, Lorazepam
Background
Avoidance of potential dangers at the cost of approach
opportunities is a hallmark of anxious behaviors across
all mammalian species [1]. Excessive and maladaptive
avoidance contributes to the development and mainten-
ance of anxiety disorders and prevents the extinction of
fearful responding in humans [2–4] and rodents [5]. In
animals, approach-avoidance conflicts are routinely
assessed with behavioral assays that make use of rodents’
innate fear of heights (elevated plus-maze (EPM) [6, 7]),
brightly illuminated (dark-light box [8]), or open (open
field test [9]) spaces, which stand in conflict with curios-
ity and a drive for spontaneous exploration. Among
these assays, the EPM is the most popular [6, 7], with
over 8500 published papers so far (Web of Science,
2017). Creating an unconditioned approach-avoidance
conflict, the EPM measures anxiety on a behavioral level
by tracking adaptive behavior in the absence of explicit
threat, punishment, or reward [6].
Although the EPM has been used for more than
30 years in laboratory rodents [6, 10] and other mammals
[11–14] to test anxiety-related behaviors, a homologous
test in humans is lacking. Instead, neurobiological re-
search has relied on experimenter-designed proxies of hu-
man behavior such as eye or joystick movements [15].
Anxiety disorders are often inappropriate exaggerations of
adaptive defensive behavior [6, 10, 16]. To understand
mechanism of mental disorders, the study of such behav-
ior is extremely valuable as it affects several diagnostic
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dimensions [16]. For example, the National Institute of
Mental Health lists ‘behavior’ as one of the units of ana-
lysis in the Research Domain Criteria Matrix [17] al-
though a behavioral measure for anxiety-related behavior
has been lacking in humans. Thus, the Research Domain
Criteria panel is currently empty [18].
Recently emerging technical and methodological ad-
vances enable behavioral tracking in humans (i.e., real-
world body movements) and can be synergistically
combined with novel mixed reality paradigms (a combin-
ation of virtual and real-world elements) providing con-
trolled experimental conditions with high realism. This
opens up new horizons in the development of standard-
ized behavioral tests whose real-world implementation
was, until now, too dangerous or laborious. Thus, well-
established behavioral assays can be translated from
rodents to humans, allowing the translational study of
mechanisms of (anxiety) behaviors across species [19].
By translating the EPM to humans, we herein present
a novel task in mixed reality that allows tracking of
approach-avoidance behavior that is ecologically (i.e., re-
semblance with the real world) and ethologically (i.e.,
relevant for the species) valid. Based on comprehensive
work in rodents, we hypothesize (1) that participants’
anxiety can be measured with identical behavioral out-
come parameters as in rodents; (2) that avoidance of
aversive open arms is related to acrophobia, while ap-
proach of open arms is related to sensation seeking in
humans; and (3) that anxioselective drugs shift the bal-
ance between human approach and avoidance behavior
as repeatedly shown in rodents [10].
Results
Human behavior on the EPM (Study 1)
In study 1, we were first interested if human behavior is
comparable to rodent behavior on the EPM. Healthy
participants (n = 100) were thus behaviorally tested. In
line with studies in rodents [6], participants spent sig-
nificantly more time on safe fractions of the maze
(closed arms and center [20]) and thereby avoided
spending time on the aversive open arms fraction (t99
= –11.89; P < 0.001, r = 0.77) and moved slower on open
compared to closed arms (t99 = –8.55; P < 0.001, r =
0.65). Importantly, these behavioral differences were
mirrored in subjective anxiety ratings (Fig. 1a; F3.4,238.5 =
52.67; P < 0.001; η2partial = 0.426).
More precisely, open compared to closed arms or cen-
ter induced higher levels of anxiety (each position P <
0.05). Similarly, higher anxiety was reported on distal
(far from center) compared to proximal (closer to cen-
ter) positions of open arms (each P < 0.001). There were
no further significant differences between fractions of
the maze. Descriptively, 98% of participants reported
having been anxious on the maze, while only two partici-
pants rated zero anxiety on the maze. Other subjective
ratings (e.g., panic, tension) can be found in Additional
file 1. Moreover, participants reported a high presence in
the virtual environment (iGroup Presence Question-
naire: spatial presence, 8.1 ± 0.6; involvement, 2.3 ± 0.8;
experienced realism, 4.8 ± 0.7) and most participants re-
ported only slight side effects (SSQ total score, 20.7 ±
2.8; nausea, 16.4 ± 2.3; oculomotor symptoms, 14.7 ± 2.2;
disorientation, 26.1 ± 5.4).
Fig. 1 a Subjective anxiety ratings (n = 100; on a 0 no anxiety to 9 very strong anxiety scale) on different positions of the elevated plus-maze (EPM)
in mean ± standard error. Open arms are in North (N) and South (S) direction, while closed arms are in East (E) and West (W) direction. Schematic
depictions of the human (b) and rodent (c) EPM. Of note, the rocks surrounding the closed arms in the human EPM (b) only appear in the virtual
environment, while the wooden real-world maze is placed on the floor of the laboratory. The closed arms in the rodent EPM (c) are surrounded
by walls
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Behavioral parameters on the EPM inform about ap-
proach and avoidance behavior as well as general activity
in rodents [6, 10]. The most established parameters to
assess anxiety reflect avoidance of open arms, such as
total time spent on open arms (time on open arms) and
number of entries to open arms. Other, less conven-
tional, parameters are latency for the first entry of an
open arm (latency 1st visit) and time until subjects
reach the end of an open arm (latency endexploration)
[21, 22], which are common for other rodent approach-
avoidance assays such as the dark-light box [23, 24]. All
four parameters measure the approach-avoidance con-
flict concerning aversive open arms. High latencies, few
visits and shorter time spent on aversive open arms
(i.e., avoidance of open arms) are interpreted as ele-
vated levels of anxiety in rodents. We hypothesized that
these parameters are also suitable to examine anxiety in
the human EPM. These parameters were thus calcu-
lated from the movement tracking data. Moreover,
other parameters that were rather attributed to loco-
motor activity in rodents [20, 25], such as total distance
covered, time on closed arms and center, entries to
closed arms, average velocity on open and closed arms,
as well as time in immobility, were collected.
The validity of these behaviors as measures of anxiety
was established by pharmacological experiments and fac-
tor analyses in rodents [20, 25]. Here, we were able to
ask participants directly after the test to rate their anx-
iety during EPM testing. We could thus compare behav-
ioral parameters between participants with subjective
high anxiety (HA) (n = 56; mean ± SE (min–max), 6.7 ±
0.2 (5–9)) and low anxiety (LA) (n = 44; mean ± SE
(min–max), 2.5 ± 0.2 (0–4)) levels. Groups were defined
using median split (median = 5, on a 0–9 scale). LA and
HA differed significantly in their subjective anxiety on
the maze in a t test (t98 = –17.87, P < 0.001, r = 0.87). In
line with our hypotheses, we found that identical out-
come parameters, as in rodents, were related to partici-
pants’ anxiety. LA spent significantly more time on open
arms (t98 = 3.31, P = 0.001, r = 0.32; Fig. 2a), entered open
arms more often (t98 = 4.05, P < 0.001, r = 0.38), and had
a significantly shorter latency first visit (t98 = –2.94, P =
0.004, r = 0.28; Fig. 2a) and latency endexploration (t98
= –4.24, P < 0.001, r = 0.39; Fig. 2a).
Interestingly, other parameters that were rather attri-
buted to locomotor activity in rodents, such as total dis-
tance covered, entries closed arms and time in
immobility [25] were also significantly altered in LA (t98
= 4.09, P < 0.001, r = 0.38; t98 = 2.04, P = 0.044, r = 0.20;
t98 = –3.84, P < 0.001, r = 0.36, respectively; Additional
file 2). Thus, these parameters are not suitable to rule
out locomotor effects of baseline locomotor activity on
anxious behavior in humans as they do not reflect base-
line locomotor activity. LA also moved faster on both
open (t98 = 4.11, P < 0.001, r = 0.38) and closed (t98 =
3.20, P = 0.002, r = 0.31) arms. Table 1 displays a detailed
description of behavioral data of LA and HA. Results of
questionnaires for Study 1 can be found in Additional
file 3.
Endocrinological and physiological responses to the EPM
(Study 1)
Earlier studies have shown that the EPM activates the
rodent stress system and increases corticosterone levels
[26]. We hypothesized that EPM testing also elicits a
transient activation of the two endogenous human stress
systems, namely the sympathetic nervous system and the
hypothalamus–pituitary–adrenal axis. As expected, we
found a main effect of time for salivary cortisol (F2.2,60.6
= 4.451, P = 0.013, η2partial = 0.142) and alpha-amylase
(F5,130 = 7.253, P < 0.001, η
2
partial = 0.218; Fig. 3). In line
with earlier experiments examining stress responses
[27], the peak concentration of alpha-amylase was en-
hanced directly after EPM testing (significantly increased
directly after compared to at all other time points; all P <
0.01), while cortisol peaked 15 min later (significantly
higher at 15 min compared to directly after and at 30, 45,
and 60 min (all P < 0.05), whereas before testing it was
lower than at 15 min but on trend level (P = 0.09); Fig. 3).
Other markers for the immediate activation of the
sympathetic nervous system are increased heart and res-
piration rate, as well as skin conductance levels (SCL).
As expected, we found a significant effect of time on
heart rate (F3.4,97.2 = 13.421, P < 0.001, η
2
partial = 0.316),
respiration rate (F5.6,155.6 = 16.102, P < 0.001, η
2
partial =
0.365), and SCL (F2,20.3 = 9.961, P < 0.001, η
2
partial =
0.499) when comparing the 11 time points assessed. All
three parameters were significantly higher throughout
the experiment compared to baseline (all P < 0.01 for
heart rate, all P < 0.001 for respiration rate, and all P <
0.05 for SCL). Additional file 4 shows an exemplary de-
piction of the physiological reaction of one participant.
Relating approach-avoidance to human traits (Study 1)
In rodents, open arm avoidance is related to elevated
anxiety, while approach is related to novelty-seeking and
curiosity [6]. We hypothesized that avoidance in humans
is also related to acrophobic fear, whereas approach is
associated with sensation seeking. Furthermore, mea-
sures of social anxiety and trait anxiety were included to
test for the specificity of the findings against presumably
unrelated forms of anxiety (i.e., social anxiety) or a gen-
eral tendency for anxious temperament (i.e., trait anx-
iety). Hierarchical multiple regression analyses revealed,
as expected, no significant contribution of anxious
temperament (Spielberger State-Trait Anxiety Inven-
tory; STAI) or social anxiety (Liebowitz Social Anxiety
Scale; LSAS) on any of the behavioral parameters
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(Additional file 5). Variance in the main outcome
measures was predicted by both acrophobia (Acro-
phobia Questionnaire; AQ), and sensation seeking
(Sensation Seeking Scale Form V; SSSV), which, as
expected, showed opposing directions (Additional file
6). In the final models, high acrophobia levels ex-
plained fewer entries of open arms (R2 = 0.135, ß =
0.33, P = 0.001), less time on open arms (R2 = 0.121, ß
= 0.26, P = 0.01), and higher latency first visit (R2 =
0.199, ß = –0.43, P < 0.001), while high sensation seek-
ing levels explained longer time on open arms (R2 =
0.121, ß = –0.21, P = 0.038) as well as shorter latency
endexploration (R2 = 0.189, ß = 0.23, P = 0.021). Inter-
estingly, sensation seeking only influenced latency
endexploration in participants with low acrophobia,
but not with high acrophobia, being reflected in a
significant SSSV*AQ interaction (R2 = 0.189, ß = 0.23,
P = 0.024).
The influence of participants’ age and sex on anxiety-
related behaviors (Study 1)
Anxiety symptoms [28] as well as 12-month and lifetime
prevalence rates for all major anxiety disorders [29] are
higher in women than in men differing across certain age
groups [30]. In an explorative analysis, we therefore com-
pared anxiety-related behaviors between men and women
and correlated behavioral measures with participants’ age.
Female participants exhibited more anxious behavior on
the EPM concerning most outcome measures (Additional
file 7). Moreover, latency open arm exploration (R = 0.223,
P = 0.026), number of entries on open arms (R = –0.237, P
= 0.018), and average velocity on open (R = –0.201, P =
Fig. 2 Barplots (a) represent mean values ± SEM for behavior on the elevated plus-maze (EPM) for low anxiety (LA) (n = 44; white) and high anxiety
(HA) (n = 56; black) participants for the parameters (from left to right): time on open arms, entries of open arms, latency first visit, and endexploration of
open arms + standard error. Exemplary trajectories for two participants are depicted under (b): The upper panel shows an LA participant and the lower
panel an HA participant. Heatmaps (c) for LA (left) and HA (right) participants reveal where participants spent most time on the EPM. The average time
spent at a position is shown in seconds – colors are defined in the legend (right bottom corner). For all depictions of the EPM, open arms are in North
and South direction and closed arms in East and West direction. *P < 0.05, **P < 0.01, ***P < 0.001
Biedermann et al. BMC Biology  (2017) 15:125 Page 4 of 13
0.45) and on closed arms (R = –0.250, P = 0.012) were
found to be correlated with participants’ age.
Demonstrating behavioral consequences of anxioselective
drugs (Study 2)
In rodents, avoidance behavior has been shown to be
sensitive to anxioselective compounds. We thus aimed
to pharmacologically modulate behavior on the EPM
using anxiolytic (lorazepam) and anxiogenic (yohimbine)
substances in healthy participants in a placebo con-
trolled, randomized, and double blind study (Study 2; N
= 51). As hypothesized, pharmacological treatment
significantly affected time on open arms (F2,48 = 7.529, P
= 0.001, η2partial = 0.239), with longer time in the loraze-
pam compared to the placebo group (t33 = 1.86, P =
0.036, r = 0.31; Fig. 4a), and a significantly shorter time
in the yohimbine compared to placebo group (t31 = 1.86,
P = 0.037, r = 0.32; Fig. 4a). Moreover, latency first visit
significantly differed between groups (F2,48 = 4.720, P =
0.013, η2partial = 0.164), with a shorter latency in the lor-
azepam compared to the placebo group (t33 = –1.90, P =
0.034, r = 0.31; Fig. 4a) and a descriptively higher latency
in the yohimbine group compared to placebo only on
trend level (t31 = –1.31, r = 0.22, P < 0.100). All other
Table 1 Behavioral measures of participants split for low anxiety (LA) and high anxiety (HA) and for all participants (n = 100)
in Study 1
LA (n = 44) HA (n = 56) All (n = 100)
Measures Mean ± SE Min Max Mean ± SE Min Max Mean ± SE Min Max
Latency open arm exploration (s) 59.6 13.3 3.2 300 118.4 14.3 65.6 300 92.6 10.3 3.2 300
Latency open arm end exploration (s) 151.6 18.4 6.4 300 242.9 12.5 30.6 300 202.7 0.1 6.4 300
Time on open arms (s) 97.9 9.3 0 213.3 58.4 7.7 0 233.7 75.8 6.2 0 233.7
Time on open arms (%) 32.6 3.1 0 71.1 19.5 2.6 0 77.9 25.3 2.1 0 77.9
Time on closed arms (s) 63.1 5.5 0 177.6 68.3 7.2 0 241.1 66.0 4.7 0 241.1
Time in center (s) 138.6 8.0 49.0 250.7 172.8 9.4 37.6 300 157.7 6.5 37.6 300
Time in center and on closed arms (s) 201.7 9.2 86.0 300 241.0 7.7 65.6 300 223.7 6.2 65.6 300
Time in immobility (s) 186.7 6.9 88.1 277.0 222.9 6.4 126.3 300 207.0 5.0 88.1 300
Average velocity on open arms (m/s) 0.051 0.004 0 0.100 0.032 0.003 0 0.110 0.041 0.002 0 0.098
Average velocity on closed arms (m/s) 0.069 0.004 0 0.130 0.050 0.004 0 0.119 0.058 0.003 0 0.129
Total distance covered (m) 14.8 0.8 4.5 29.5 10.6 0.6 0.7 20.1 12.4 0.5 0.7 29.5
Number of entries open arms (n) 4.7 0.4 0 7 2.8 0.3 0 7 3.6 0.3 0 10
Number of entries closed arms (n) 3.2 0.2 0 1 2.6 0.2 0 7 2.9 0.2 0 7
Measures are given as mean ± SE
SE standard error, Max maximum values, Min minimum
Fig. 3 Physiological reactions to the elevated plus-maze (EPM) in Study 1. Barplots (a–c) show significant increases of heart (n = 30) and respiration rate
(n = 29) as well as skin conductance levels (n = 11) throughout EPM testing compared to baseline. Barplots (d and e) show means for saliva cortisol
(n = 28, upper panel) and alpha-amylase levels (n = 27, lower panel) before (T0) and directly after (T1) as well as at 15 min (T2), 30 min (T3), 45 min (T4),
and 60 min (T5) after the experiment. Values are given as means ± standard error. *indicate significant differences between baseline and all
other intervals for (a–c) and post hoc significance at P < 0.05 comparing cortisol at T2 to T1, T3, T4, and T5 and comparing amylase at T1 to all
other time points
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parameters did not show significant group differences.
Table 2 shows a detailed overview of behavioral data.
The pharmacological challenge also exerted the ex-
pected effect on participants’ subjective anxiety ratings
(F2,48 = 4.070, P = 0.023, η
2
partial = 0.145; Fig. 4c), with
significantly anxiolytic effects in the lorazepam com-
pared to the placebo group (t33 = –2.00, P = 0.027, r =
0.34) and descriptively anxiogenic effects of yohimbine
compared to placebo (t31 = 0.87, P = 0.196, r = 0.15).
Additional descriptions of group comparisons regarding
subjective ratings can be found in Additional file 8. The
main outcomes were corroborated with an additional
MANCOVA including age and sex as covariates (time
on open arm F2,46 = 6.926, P = 0.002, η
2
partial = 0.231; la-
tency first visit F2,46 = 4.575, P = 0.015, η
2
partial = 0.166;
subjective ratings of anxiety F2,46 = 3.829, P = 0.029,
η2partial = 0.143).
Replicating the psychophysiological effect observed in
Study 1, a significant effect of time on all three measures
was revealed (heart rate F3.8,148.8 = 26.832, η
2
partial =
0.408; respiration rate F5.9,254.2 = 26.612, η
2
partial = 0.364;
SCL F3.1,103.2 = 37.713, η
2
partial = 0.533; all P < 0.001). Post
hoc, all parameters at all time points showed signifi-
cantly higher values compared to baseline (each P <
Fig. 4 Barplots depicting behavior of participants (a) from lorazepam- (n = 18), placebo- (n = 17), and yohimbine-treated (n = 16) groups concerning
time on open arms and latency first visit as well as subjective anxiety ratings (c). Heatmaps (b) for the groups reveal where participants spent
most time on the elevated plus-maze. The legend shows the average time spent at a position in seconds. Open arms are in North and South
direction and closed arms in East and West direction. Values are given as means ± standard error. *P < 0.05 significance in post hoc tests in
comparison to the placebo group
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0.001). Moreover, there was a significant time*treatment
interaction for heart rate (F7.6,148.8 = 2.242, P = 0.030,
η2partial = 0.103) but without significant post hoc effects.
Discussion
Using a mixed reality paradigm, we herein demonstrate
a translation of the EPM from rodents to humans. This
is, to our knowledge, the first ecologically valid assay to
track actual human approach-avoidance behavior in the
laboratory to assess anxiety on a behavioral level.
Other approaches to translate behavioral assays into
humans have only emerged recently. For example, the
open field test [31] and Morris water maze [32] were
successfully translated. However, both tasks require im-
mense logistical efforts limiting comparability and
standardization across laboratories. It would thus be
advantageous to develop these tasks in virtual reality
[19], as has been done with fear conditioning paradigms
[33–35]. Other approaches used computer game para-
digms for the radial arm [36] and Morris water maze
[37] or approach-avoidance conflicts [38–41]. These
computer games, though highly standardized, have the
disadvantage of lower immersion compared to real-
world, virtual- or mixed-reality paradigms and they
only assess proxies of human behavior. Importantly, the
human EPM is easily transferrable to other laboratories
allowing comparability and grouping of data across la-
boratories. With the herein performed translation, fur-
ther studies to identify species-conserved mechanisms
likely implicated in anxiety and anxiety disorders are
feasible. Translation of rodent tasks to humans could
thus help to bridge preclinical science and clinical
studies and may have an important role in the develop-
ment of new anti-anxiety drugs [19].
Our data indicate good validity according to common
definitions [42]. Firstly, presence and immersion in the
mixed-reality were high. Moreover, participants’ anxiety
could be observed by experimenters as participants often
gasped at the beginning of the paradigm and moved pre-
cariously and slower on open arms (see, for example, the
deep inhalation in Additional file 4 in response to EPM
start). Thus, face validity (the ability of a test to measure
what it is supposed to measure) can be assumed. Sec-
ondly, content validity (the extent to which a measure rep-
resents all facets of a given construct) was fulfilled – on a
physiological level, the EPM stimulated the sympathetic
nervous system and the hypothalamus–pituitary–adrenal
axis, demonstrated by a rise in SCL, heart and respiration
rate at the beginning of the experiment and elevated sali-
vary alpha-amylase and cortisol levels after behavioral test-
ing. On a behavioral level, participants spent most time on
save compartments of the EPM (i.e., center and closed
arms) and moved slower on open versus closed arms. On
a subjective level, participants stated after the experiment
that they had felt more anxious on open versus closed
arms and center. Thirdly, concurrent validity (the measure
in question is the same as another outcome assessed at
the same time) can be assumed as we found a high correl-
ation between subjective anxiety ratings and behavioral
outcomes – HA participants displayed significantly more
avoidance of aversive open arms compared to LA.
Fourthly, predictive validity (the ability to predict behavior
on a related measure) was met as we found significant as-
sociations of behavioral measures with trait measures of
acrophobia and sensation seeking. Interestingly,
Table 2 Behavioral measures for Study 2 comparing participants from lorazepam, placebo, and yohimbine groups
Measures Lorazepam Placebo Yohimbine
Mean ± SE Min Max Mean ± SE Min Max Mean ± SE Min Max
Latency open arm exploration (s) 42.1 9.5 5.3 113.8 92.9 25.8 9.8 300 148.9 34.4 4.2 300
Latency open arm end exploration (s) 133.6 26.6 15.5 300 177.1 28.7 17.6 300 193.4 31.7 11.5 300
Time on open arms (s) 131.3 9.6 52.8 187.4 97.8 15.5 0 195.0 58.1 14.6 0 146.7
Time on open arms (%) 43.8 3.2 17.6 62.5 32.6 5.2 0 65.0 19.4 4.9 0 48.9
Time on closed arms (s) 46.1 5.6 10.8 105.3 39.1 9.5 0 165.3 53.3 15.4 0 218.2
Time in center (s) 122.1 9.7 77.0 207.8 162.4 18.4 79.4 300 187.9 19.5 81.1 300
Time in center and on closed arms (s) 168.2 9.5 111.9 246.4 201.6 15.6 104.2 300 241.2 15.6 152.6 300
Time in immobility (s) 198.2 8.4 131.6 269.5 205.7 15.7 86.0 300 219.4 13.2 114.6 290.8
Average velocity on open arms (m/s) 0.044 0.004 0.019 0.083 0.040 0.007 0 0.099 0.032 0.007 0 0.081
Average velocity on closed arms (m/s) 0.074 0.006 0.032 0.129 0.070 0.012 0 0.148 0.061 0.011 0 0.139
Total distance covered (m) 13.6 1.0 6.5 25.1 12.6 1.8 0 27.9 11.1 1.4 3.8 22.9
Number of entries open arms (n) 4.4 0.6 0 11 4.3 0.8 0 10 2.9 0.7 0 9
Number of entries closed arms (n) 2.9 0.3 1 6 2.4 0.4 0 5 2.1 0.4 0 5
Measures are given as mean ± SE
SE standard error, Min minimum, Max maximum values
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acrophobia and sensation seeking both influenced behav-
ior in opposite directions, which is in line with earlier the-
ories that all emotional behaviors are controlled by at least
two opponent motivational systems [43]. While acropho-
bia was related to avoidance (i.e., higher traits had longer
latencies), sensation seeking was related to approach (i.e.,
shorter latencies). In rodents, it was demonstrated that
anxioselective compounds, brain lesions, environmental
factors, and genetic manipulations can shift the balance of
the conflict between approach and avoidance [6, 43, 44].
To further prove predictive validity, we corroborated this
bidirectional sensitivity of the EPM to manipulations of
anxiety [7] by anxioselective effects of lorazepam and yo-
himbine in humans. Since construct validity (the ability of
a test to measure the intended construct) is met if content
and criterion (i.e., concurrent and predictive) validity are
fulfilled, we can also assume construct validity. To our
knowledge, this is the first validation of a human
approach-avoidance test for innate, unconditioned anxiety
that measures actual human behavior.
Outlook and limitations
Our data were obtained from a healthy sample spanning a
large dimension of anxiety-related traits. Future work
might focus on individuals that are at the extreme ends of
these dimensions. Moreover, to study treatment effects,
repeated exposure to the EPM needs to be implemented
in the future to perform longitudinal research, as in ro-
dents [45]. The virtual part of the human EPM can be
easily adapted (e.g., height of the maze, incentives for ap-
proach behavior, a different environment or inclusion of
avatars as assisting partners) for longitudinal research and
to suit populations with different needs such as children,
elderly people, or psychiatric patients. Although we found
in explorative analyses that age and sex influence anxiety-
related behavior on the human EPM, these factors need to
be addressed in the future with a larger sample size, in-
cluding menstrual cycle phase and contraceptive use as
co-variates, as well as more participants from older age
ranges as only 15% of participants from our sample in
Study 1 were aged between 30 and 40 years and only 4%
between 40 and 50 years.
Conclusion
Maladaptive or excessive avoidance is a hallmark of anx-
iety disorders and places a significant burden on affected
patients. To date, research on anxiety disorders was
complicated by the absence of a standardized laboratory
test to study actual approach-avoidance behavior in
humans. With the herein developed human EPM, anx-
iety can be inflicted and measured in an ambiguously
threatening environment in mixed reality. Thus, we
introduce a standardized and easily transferable para-
digm for the research of human anxiety on a behavioral
level. Identical outcome parameters in the human and
rodent EPM facilitate translational research across
species.
Methods
Participants and procedures
Healthy individuals aged between 18 and 50 years were
invited to participate through a variety of means, includ-
ing a popular local website for biomedical research re-
cruitment, word of mouth, and a notice at local
Universities. All laboratory procedures were performed
between 1 to 6 pm for Study 1 and between 9 am to
noon for Study 2. All participants received a telephone
interview before inclusion to rule out somatic or psychi-
atric disorders as well as current drug use. Participants
agreed to abstain from eating, drinking, smoking, and
physical exercise for 2 hours prior to testing. Participants
were informed about the procedure and gave written in-
formed consent. All experiments were approved by the
local ethics committee (Ärztekammer Hamburg,
Germany) and the study was conducted in accordance
with the good clinical practice guidelines as defined in the
Declaration of Helsinki (2013).
For Study 1, 104 healthy participants were recruited.
For pilot testing, a first subgroup of participants (n = 33;
male = 16, female = 17) were recruited and psycho-
physiological recordings and saliva sample collection
5 min before (T0), directly after (T1), and 15 (T2), 30
(T3), 45 (T4), and 60 min (T5) after behavioral testing
were performed only in this subgroup. The subjective
experience of the virtual reality immersion was assessed
using iGroup presence questionnaire [46] and side ef-
fects were measured using simulator sickness question-
naire [47]. Additionally, 71 participants were recruited
as part of a larger ongoing data collection within the
framework of a collaborative research center (SFB TRR
58). Participants provided personality- and anxiety-
related questionnaires and were subjected to behavioral
testing on the EPM. Participants were screened to be
free from psychiatric disorders by the MINI diagnostic
interview [48] prior to inclusion in the study. Three par-
ticipants were excluded due to technical problems and
one because of not following the study instruction lead-
ing to a sample size of n = 100 (female = 64, male = 36;
age = 26.2 ± 0.5 years).
For Study 2, 57 participants (female = 34, male = 23; age
= 26.9 ± 0.6 years) randomly received 1 mg of the benzodi-
azepine lorazepam, 20 mg of the alpha-2-adrenergic recep-
tor antagonist yohimbine, or placebo in a double blind
manner 60 min before behavioral testing. Six participants
were excluded from behavioral testing or the analyses due
to technical problems (n = 2) or strong side effects (‘strong
sedation’, n = 4) before behavioral testing (Additional file 9).
From the remaining 51 participants (female = 29, male = 22;
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age = 27.3 ± 0.6 years), 18 received lorazepam, 17 placebo,
and 16 yohimbine. There were no significant differences
concerning sociodemographic parameters and trait ques-
tionnaires between the three groups (Additional file 10). In
all participants of Study 2, psychophysiological recordings
were performed, while analyses of endocrinological mea-
surements were not feasible because interaction of the
medication with alpha-amylase levels was suspected and
participants were tested in the morning, making an over-
shadowing of cortisol responses likely.
Four anxiety-related questionnaires from the collab-
orative research center sampling were chosen a priori;
these were STAI [49], AQ [50], LSAS [51], and SSSV
[52]. After behavioral testing, participants rated their
anxiety level on the EPM on a scale from 0 (no anxiety)
to 9 (very strong anxiety) as well as their anxiety level
on different positions of the EPM. Moreover, we asked
for side effects and other emotions (such as ‘having
panic’, see Additional files 1 and 8) on a scale from 0
(not at all) to 9 (very strongly). For Study 2, state anxiety
and side-effects of medication were assessed 5 min be-
fore behavioral testing.
Human EPM
The human EPM consists of a real-world wooden maze
combined with a representation of this maze in virtual
reality. The real-world maze consists of four wooden
arms (width 30 cm, height 20 cm). Each arm has a
length of 175 cm, covering in total 350 × 350 cm, within
an experimental room (550 × 550 cm) with two virtual
reality tracking systems (HTC Vive Base Station®, Seattle,
USA) attached at 250-cm height at opposite walls. Par-
ticipants entered the room with closed eyes and were
guided by one of the experimenters towards the maze.
Participants received a headset (HTC Vive®, Seattle,
USA) and noise canceling headphones (Bose QuietCom-
fort 35®, Framingham, USA) and were instructed to open
their eyes. After checking the vision of participants in a
baseline graphical environment, the virtual reality soft-
ware (A+ cross®, VirtualRealWorlds.com, Germany) was
started. Participants found themselves in a 550 × 550 cm
large virtual room with a virtual wooden plus-maze
(350 × 350 cm) in front of them. Importantly, the virtual
reality plus-maze and the physical real-world plus-maze
had the same shape, material and size as well as position
in the virtual and real world. A recorded voice instructed
participants to step on the maze and walk slowly to-
wards the center of the maze where participants had to
wait for 60 s to allow for baseline measurements. Fur-
ther, they were instructed that they would be allowed to
explore the environment on the maze once the scene
had changed. The behavioral experiment started after
90 s and participants found themselves in a new
environment. In the new scenario, only the virtual plus-
maze remained unchanged. Instead of being in a virtual
room, the maze was placed on a virtual rocky mountain
surrounded by water. Two opposite arms (here termed
closed arms as in the rodent EPM) and the center of the
maze were surrounded by rocks, while the other arms
reached out over the water, which was roughly 55 m
below (open arms). Simultaneously with the change of
the virtual environment, two ventilators were started in
the experimental room to increase presence in the vir-
tual environment, as previously suggested [53, 54]. The
ventilators were placed at the end of the arm that partic-
ipants were initially facing in order to give the impres-
sion of a cool wind from ahead. Participants were
allowed to explore the EPM for 300 s. After the scenario
ended, participants removed their headsets and left the
room. Additional file 11 shows simultaneous video re-
cordings from different perspectives during the EPM.
Data recording and synchronization of the EPM
Before experimental testing, the virtual maze was syn-
chronized with the real-world maze using a controller
(HTC Vive controller®, Seattle, USA), a purpose-
designed mounting device, and a purpose-designed soft-
ware (A+ cross®). During the alignment of the virtual en-
vironment and the physical maze, the calibration
software (A+ cross®) axis-aligned the 3D world space co-
ordinate system with the arms of the physical maze. The
world space coordinate system was created with its ori-
gin at the center of the maze, its x-axis aligned with the
closed arms, and its z-axis aligned with the open arms of
the plus-maze.
Headset position and orientation during a running
experiment were sampled at 5 Hz to obtain, for each
sampling point i at time t , a set of 3D positions p!i
¼ pix; piy; piz
 
and 3D orientations r!i ¼ rix; riy; riz
 
.
These measurements were subsequently analyzed auto-
matically by the software (A+ cross®) to evaluate partici-
pants’ movement patterns on the maze. A sample point
pi counts towards time spent on one arm if the absolute
position on one of the axes, and thus distance from cen-
ter, is larger than a pre-defined threshold value. The total
time spent on one of the open arms ( to ) and the closed
arms (tc) is calculated as to;c ¼
P
ti jpix;zj > threshold
h i
.
The threshold value was determined manually by pla-
cing markers on the arms and evaluating the headset
position for the time points when a participant stepped
onto an arm with both feet. After this value had been
obtained, it was used for the automatic analyses.
A participant’s change between the areas defined by
the threshold value was evaluated at a maximum of one
area change per second. This was done to prevent
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positional tracking jitter from creating false information
about area changes for participants that were standing at
a position very close to the threshold value.
In addition to the time spent in the different areas of
the maze, all movements of the headset were calculated
as average velocities v!o; c whenever pix; z > thresh o; c½  and
pi1x;z > thresh o; c½ .
Sample points for which the inverse case, pix;z
> threshold and pi1x;z < threshold , was measured were
counted towards the total number of entries n o; c½  to one
of the arms.
Psychophysiological measurements
SCL, respiration, and heart rate (ECG) were recorded
using BioNomadix wireless physiology devices and a
BIOPAC MP150 data acquisition system and were ana-
lyzed using Acqknowledge 4.4.1 software (Biopac Sys-
tems, Goleta, CA, USA). Skin conductance Ag/AgCl
electrodes were attached 10 min before behavioral test-
ing to the index and middle fingers in Study 1 and on
the palmar surface of the non-dominant hand in Study
2. Baseline levels were recorded 30 s before behavioral
testing and average levels were compared to average
levels of 30-s intervals during behavioral testing. In
Study 1, 21 (66%) SCL datasets had to be excluded due
to electrode detachment during behavioral testing. In
Study 2, we changed positioning and type of electrodes
and only 15 (29%) had to be excluded. Moreover, 3 (9%)
respiration data from Study 1 and 5 (10%) from Study 2
as well as 2 (6%) ECG data from Study 1 and 9 (18%)
ECG data from Study 2 had to be excluded due to poor
data quality. To reduce exclusion rate, missing values
due to movement artifacts were replaced with the means
of nearby values if a value before and after the missing
value existed.
Endocrinological measurements
Participants received oral instructions on the correct use
of the Salivette salivary collection device (Sarstedt AG,
Nümbrecht, Germany). Samples were centrifuged and
saliva stored at –80 °C until further analysis. Cortisol
was determined by radioimmunoassay (DRG, Marburg,
Germany). Inter- and intra-assay coefficients of variation
were below 8% and detection limit was 0.5 ng/mL.
Alpha-amylase was determined by using a commercial
liquid phase enzymatic assay (RE80111, IBL Inter-
national, Hamburg, Germany). Intra- and inter-assay co-
efficients of variance were below 7%, the detection limit
was 25 U/mL.
Statistical analyses
Statistical analyses were carried out using IBM SPSS Sta-
tistics 22.0 (IBM Corp., Armonk, NY, USA). A repeated
measures ANOVA was performed to compare subjective
anxiety ratings on different positions of the EPM (Fig. 1)
as within-subject factors followed by post hoc compari-
sons using Bonferroni correction. Greenhouse–Geisser
correction for sphericity was applied when appropriate.
Paired t tests were used to compare behavior on open
versus closed arms. For Study 1, participants were di-
vided into subgroups for participants with subjective LA
and HA ratings using median split. Two-sided t tests
were used to compare behavioral measures between
groups. According to our hypotheses, four hierarchical
multiple regression analyses for time on open arms, la-
tency first visit, latency endexploration, and entries open
arm, including AQ as first, SSSV as second, and STAI as
well as LSAS as the third step into the regression model,
were performed. Thereafter, a second set of regression
analyses was performed, including only the significant
regressors as well as an interaction term of these signifi-
cant regressors in a second step. To avoid multicolleral-
ity, mean centered values for factors were used.
Endocrinological measurements of Study 1 were ana-
lyzed using repeated measures ANOVA with time points
(T0–T5) as the within-subject factor. In line with previous
research [27], we hypothesized an increase of cortisol ap-
proximately 15 min after exposure to the EPM and of
alpha-amylase directly after the experiment. Thus, one-
sided post hoc paired t tests were performed comparing
cortisol levels of T2 and alpha-amylase levels of T1 with
all other time points. Psychophysiological data were ana-
lyzed using repeated measures ANOVA with the 11 inter-
vals (baseline, 0–30 s, 30–60 s, etc.) as within-subject
factors, followed by post hoc paired t tests comparing
baseline with all other intervals. SCL data were trans-
formed to logarithmic values (logarithmus naturalis (ln)).
In Study 2, sociodemographic factors and trait ques-
tionnaires were compared using MANOVA or χ2 tests of
association between the three groups. Anxiety ratings
and behavior were analyzed using MANOVA with treat-
ment (lorazepam, yohimbine, placebo) as the factor.
Earlier research provided strong evidence that the EPM
is sensitive to pharmacological manipulation with benzo-
diazepines and yohimbine in rodents [10] and that 1 mg
of lorazepam is anxiolytic and 20 mg of yohimbine is
anxiogenic in humans [55, 56]. Thus, MANOVA was
followed due to directed hypotheses by post hoc one-
sided t tests to compare each pharmacological group with
placebo. Psychophysiological data were analyzed in ana-
logy to Study 1, but including treatment as a between-
subject factor, followed by appropriate post hoc tests.
All data are given as mean ± standard error (SEM).
Statistical significance was set at P < 0.05. Effect sizes are
given as η2partial for ANOVAs and as r for t tests. Original
data used in this study are displayed in Additional files
12, 13, 14, 15 and 16.
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Additional files
Additional file 1: Table S1. Subjective ratings on a scale from 0 (not at
all) to 9 (very strongly) that were collected after behavioral testing in
Study 1 for all participants, as well as for subgroups with low and high
subjective anxiety (LA, HA). (DOCX 16 kb)
Additional file 2: Figure S1. Total distance covered and entries of
closed arms in Study 1 (a) and Study 2 (b). These measures are used to
assess baseline locomotor activity in the rodent EPM. However, in the
human EPM they also differ between LA and HA and are thus not
suitable as measures for baseline locomotor activity. Some participants
with very high anxiety did not move on the EPM due to behavioral
inhibition or freezing. Thus, total distance covered can be affected by
anxiety on the human EPM. (TIFF 93 kb)
Additional file 3: Table S2. Results of questionnaire data from
Spielberger State-Trait Anxiety Inventory (STAI) trait subscore, Acrophobia
Questionnaire (AQ), Liebowitz Social Anxiety Scale (LSAS), and Sensation
Seeking Scale Form V (SSSV), including respective subscores from Study
1, given in mean ± standard error (SE), minimum (min), and maximum (max)
values. (DOCX 20 kb)
Additional file 4: Figure S2. An exemplary depiction of the
psychophysiological reaction to the elevated plus-maze of one participant.
The black arrow marks the change from baseline testing (virtual room) to
the beginning of the elevated plus-maze test (being in a new virtual
environment on a rocky mountain above the sea) and the red arrow
marks the moment when the participant entered the open arm for the
first time. (TIF 1453 kb)
Additional file 5: Table S3. Results of regression analyses with
Acrophobia Questionnaire (AQ), Sensation Seeking Scale Form V
(SSSV), Spielberger State-Trait Anxiety Inventory (STAI), and Liebowitz
Social Anxiety Scale (LSAS) (*P < 0.05, **P < 0.01, and ***P < 0.001).
(DOCX 22 kb)
Additional file 6: Table S4. Results of multiple regression analyses with
mean centered values for Sensation Seeking Scale Form V (SSSV) and
acrophobia questionnaire (AQ) as well as interaction term AQ × SSSV;
(*P < 0.05, **P < 0.01, and ***P < 0.001). (DOCX 20 kb)
Additional file 7: Table S5. Behavioral data of participants split for sex
(N = 100). Mean ± standard error (SE), minimum (min), maximum (max)
values. (DOCX 16 kb)
Additional file 8: Table S6. Subjective ratings on a scale from 0 (not at
all) to 9 (very strongly) that were collected after behavioral testing in
Study 2. (DOCX 16 kb)
Additional file 9: Table S7. Side effects after medication in Study 2.
Data were collected directly before behavioral testing (i.e., 55 min after
medication). (DOCX 19 kb)
Additional file 10: Table S8. Results of questionnaire data from Study
2 Spielberger State-Trait Anxiety Inventory (STAI) trait subscore, acrophobia
questionnaire (AQ), Liebowitz Social Anxiety Scale (LSAS), and Sensation
Seeking Scale Form V (SSSV) including respective subscores, given in mean
± standard error. (DOCX 17 kb)
Additional file 11: Movie 1. Simultaneous video recordings from
different perspectives during EPM performance. Of note, two authors
participated in video filming, thus no real participant is shown.
(AVI 276316 kb)
Additional file 12: Supplemental file 1. Original data from Study 1.
(CSV 23 kb)
Additional file 13: Supplemental file 2. Original endocrinological data
from Study 1. (CSV 1 kb)
Additional file 14: Supplemental file 3. Original psychophysiological
data from Study 1. (CSV 5 kb)
Additional file 15: Supplemental file 4. Original data from Study 2.
(CSV 9 kb)
Additional file 16: Supplemental file 5. Original psychophysiological
data from Study 2. (CSV 11 kb)
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